AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03843697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An App for reminding patients to take their medication
Description: Open-label, single-center study, up to 20 adults (>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
Study NCT03552523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
Study NCT03552523 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
Study NCT03143738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous anesthesia of adductor canal
Description: After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
Study NCT03143738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous anesthesia of femoral nerve
Description: After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
Study NCT03286660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chair Rise Tests and short questionnaire
Description: Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise
Study NCT03585517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM23
Description: T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
Study NCT03039465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Trans-Esophageal Prosthesis
Description: This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
Study NCT04733625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: single injection of Vitamin D (200000 I.U
Study NCT03143738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
Study NCT03995316 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual + MMB 2.0
Description: Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
Study NCT03995316 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual Only
Description: NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
Study NCT02871505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin G
Study NCT00808002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg every 12 hours
Study NCT00808002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg every 12 hours
Study NCT00808002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg every 12 hours
Study NCT00808002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine
Description: Tenofovir/Emtricitabine 300/200 mg every 24 hours
Study NCT00808002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tenofovir/Emtricitabine 300/200 mg every 24 hours
Study NCT02083289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Study NCT02083289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Study NCT01666093 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty of the lower limbs vessels
Description: Standard revascularization techniques will be used in the study
Study NCT04811144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG dental laser
Description: To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
Study NCT03999632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary modification with introduction of Mankai
Description: Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
Study NCT03050190 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Therapeutic 4SCAR19 cells
Description: Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
Study NCT03239327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT00902811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM(FDC)
Description: Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
Study NCT00902811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AM(LT)
Description: Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
Study NCT00902811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL
Description: Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
Study NCT00902811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP
Description: 40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group \<6yrs of age, a subdivision according to weight is made
Study NCT00902811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA(FDC)
Description: Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
Study NCT00098397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00098397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT03714568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3326
Description: TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
Study NCT03714568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
Study NCT04733625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo medication
Study NCT00802672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Cream
Description: topical cream
Study NCT00802672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loprox Cream 0.77%
Description: topical cream
Study NCT00802672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical cream
Study NCT01254084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gynostemma Pentaphyllum tea
Description: 6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
Study NCT04214353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-PET/CT
Description: All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
Study NCT04214353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18FDG-PET/CT
Description: All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
Study NCT01254084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
Study NCT04540237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
Study NCT01228175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25mg look alike riboflavin tablets to match active study medication.
Study NCT01228175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
Study NCT01377246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Description: 40 mg every 28 days (in two intragluteal 20 mg injections) for three years
Study NCT01377246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution.
Description: At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
Study NCT01111110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static then anti-static chamber
Description: albuterol with Static then anti-static chambers
Study NCT01663038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel and Aspirin separate combination, single dose
Study NCT01663038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination of clopidogrel/Aspirin
Description: Fixed dose combination of clopidogrel/aspirin
Study NCT01663038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT05102058 — intervention group
Intervention type: DRUG
Intervention: Magnesium-Dexmedetomidine
Description: Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
Study NCT02903017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid 5%
Description: Via nasogastric tube, 100 mL
Study NCT04195295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane
Description: * In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane
Study NCT04195295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material
Description: Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.
Study NCT04195295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement procedure in intrabony defects.
Description: full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
Study NCT01024738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush half mouth twice daily for four days.
Study NCT01024738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily
Study NCT01375452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study NCT01375452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study NCT01797588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor-canal block
Description: The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
Study NCT01797588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular infiltration
Description: Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
Study NCT02965508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Primary Care
Description: Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
Study NCT02965508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Office based care
Study NCT01269099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA
Description: IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
Study NCT01269099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control group (No-PCA group)
Study NCT02301819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veno-arterial extracorporeal membrane oxygenation (ECMO)
Description: Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
Study NCT02301819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early conservative therapy according to standard practice
Description: Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
Study NCT02903017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Via nasogastric tube, 100 mL
Study NCT00984191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT-CT
Description: 99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Study NCT03769701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring capillary glucose (SMCG)
Description: To measure the capillary glucose with a glucometer according to the assigned group.
Study NCT03769701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-monitoring capillary glucose (SMCG)
Description: To measure the capillary glucose with a glucometer according to the assigned group.
Study NCT02332902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
Study NCT00855855 — intervention group
Intervention type: BIOLOGICAL
Intervention: DTaP-IPV/Hib
Description: 0.5 mL, Intramuscular
Study NCT03998449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against cholera
Description: Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
Study NCT02400775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets
Study NCT01862068 — intervention group
Intervention type: OTHER
Intervention: Blood samples and clinical data
Description: Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
Study NCT01862068 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample will be performed at inclusion from all healthy patients
Study NCT03530137 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Home
Description: An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
Study NCT03530137 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).
Description: ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
Study NCT03530137 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HealthySteps
Description: Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
Study NCT03041792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide
Study NCT03041792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01568125 — intervention group
Intervention type: DRUG
Intervention: Incretin-related drugs
Description: DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.